Key facts
- House Rx’s last known valuation is $253.0M (Nov 2025).
- It has raised $84.9M across 1 recorded rounds; the latest was Early Stage VC (Series B) ($55.0M) in Nov 2025.
- Notable investors include Khosla Ventures, Bessemer Venture Partners, New Enterprise Associates, First Round Capital, Reform Ventures — 12 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for House Rx
Funding rounds
1 roundsAbout House Rx
Operator of a technology-enabled service company intended to make specialty medication more accessible and affordable. The company partners closely with specialty clinics all over the country to deliver combined medical and pharmacy care to all patients, enabling clinics to dispense specialty medications to their patients, physicians, and pharmacists to collaborate on patient care.
- Industry
- Other Healthcare Technology Systems
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2021
- Employees
- 250
- Website
- houserx.com/
- Ownership
- Privately Held (backing)
House Rx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in House Rx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on House Rx in its N-PORT filings yet. We sweep new filings monthly.